



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2014

Genetic variants of methionine metabolism and DNA methylation

Bleich, Stefan ; Semmler, Alexander ; Frieling, Helge ; Thumfart, L ; Muschler, Marc ; Hillemacher, Thomas ;
Kornhuber, Johannes ; Kallweit, Ulf ; Simon, Matthias ; Linnebank, Michael

DOI: <https://doi.org/10.2217/epi.14.54>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-104646>

Journal Article

Accepted Version

Originally published at:

Bleich, Stefan; Semmler, Alexander; Frieling, Helge; Thumfart, L; Muschler, Marc; Hillemacher, Thomas; Kornhuber, Johannes; Kallweit, Ulf; Simon, Matthias; Linnebank, Michael (2014). Genetic variants of methionine metabolism and DNA methylation. *Epigenomics*, 6(6):585-591.

DOI: <https://doi.org/10.2217/epi.14.54>

Genetic variants of methionine metabolism and DNA methylation

Running title: Genetic variants of methionine metabolism and DNA methylation

Keywords: DNA methylation; homocysteine; methionine metabolism; single nucleotide

Bleich S^{1*}, Semmler A^{2*}, Frieling H¹, Thumfart L¹, Muschler M¹, Hillemacher T¹,

Kornhuber J¹, Kallweit U², Simon M³, Linnebank M²

¹Molecular Neuroscience Laboratory; Department of Psychiatry, Socialpsychiatry and Psychotherapy; Hannover Medical School (MHH), Hannover, Germany

²Dept. Neurology, University Hospital Zurich, Switzerland

³Dept. Neurosurgery, University Hospital Bonn, Bonn, Germany

*BS and SA contributed equally

Correspondence: PD Dr. Michael Linnebank, Dept. of Neurology, University Hospital Zurich,

Frauenklinikstrasse 26, 8091 Zurich, Switzerland. Phone: +41 44 2555544. Fax: +41 44

2554507. E-mail: michael.linnebank@usz.ch

polymorphism

Abstract

Altered DNA methylation is associated with important and common pathologies such as cancer. The origin of altered DNA methylation is unknown. The methyl groups for DNA methylation are provided by methionine metabolism. This metabolism is characterized by a high inter-individual variability, which is in part explained by genetic variants. In a cohort of 313 individuals derived from a family-based study with index cases of cerebrovascular disease we analysed whether global methylation of leukocyte DNA was associated with age, gender, homocysteine plasma levels or functionally relevant genetic variants. We observed an association of the G-allele of the methionine synthase variant c.2756A>G (D919G) with global methylation (% methylation \pm 1 standard deviation, AA: 41.3 \pm 14.9; AG: 36.4 \pm 18.2; GG: 30.8 \pm 16.9; F=4.799; p=0.009). The methionine synthase variant c.2756A>G is associated with various types of cancer. Our data suggest that an impact on DNA methylation may contribute to the clinical relevance of the methionine synthase variant.

Keywords: DNA methylation; homocysteine; methionine metabolism; single nucleotide polymorphism

Introduction

DNA methylation is a well-known epigenetic mechanism and associated with important and common pathologies such as cancer [1]. The origin of altered DNA methylation, however, remains unclear. Recently, a variety of inactivating mutations in genes controlling the epigenome have been described in whole genome sequencing of human cancers [2,3]. These mutations have the potential to disrupt DNA methylation patterns and therefore contribute to disease development as much as epigenetic silencing is able to cause the loss of function of genes and predisposes to genetic mutations, leading to an interplay between genetic mutations and epigenetic alterations . Several human cancers show mutations of epigenetic modifiers that presumably lead to altered DNA methylation. In acute myeloid leukemia DNA methyltransferase 3a (DNMT3A) mutations have been found to be associated with differences in global DNA methylation patterns [4], in colorectal cancer mutational inaction of DNMT1 was described [5], and isocitrate dehydrogenase 1/2 (IDH 1/2) mutated gliomas show distinct epigenetic profiles, characterized by a high frequency of methylated CpG islands [6].

The human methionine metabolism is closely linked to DNA synthesis and epigenetics (Figure 1). Methionine is activated to S-adenosyl-methionine (SAM), which is the only and ubiquitous methyl donor for DNA methylation mediated by the DNA methyltransferases. Methionine metabolism is known to be influenced by several factors including genetic variants and nutrition. Some genetic variants of methionine metabolism have been reported to be associated with vascular disease, neurodegeneration or cancer [7]. It is therefore plausible to assume that some genetic variants of the methionine metabolism could influence DNA methylation. This study investigated whether genetic variations of methionine metabolism influence the global DNA methylation in sample of individuals of whom several genetic variations of methionine metabolism were already known [8].

Materials and Methods

For this study we used a gDNA library consisting of 313 gDNA samples of German individuals of white Caucasian ancestry from an ongoing study investigating the inheritance of the wall thickness of the common carotid intima media thickness [8,9]. Of the 313 individuals, n= 85 were patients with vascular disease (mean age in years \pm 1 standard deviation: 63.4 \pm 8.9; 22% female), n= 68 were spouses (62.0 \pm 8.7 years; 79% female), and n= 160 were offspring (35.0 \pm 7.9years, 51% female) of these patients and spouses. All patients with clinical or laboratory signs of inflammation, including changes in complete blood count (CBC) and increases of C-reactive protein (CRP), were excluded from the study. All patients with laboratory signs of decreased kidney function were excluded from the study. Individuals were of Caucasian origin and lived in the area of Bonn, Germany. The patients with vascular disease were defined by an increase of the intima-media thickness of the common carotid artery [9]. Spouses and offspring had no increase of the intima-media thickness and no history of vascular events. For these 313 individuals, genotypes were known for the following genetic variants of methionine metabolism, i.e. CBS c.844_855ins68 (change of transcript levels, Genbank Number S78267.1)[10], DHFR c.594+59del19bp (change of transcript levels, rs70991108)[11], MTHFR c.677C>T (A222V, rs1801133) [12] and c.1298A>C (E429A, rs1801131) [13], MTR c.2756A>G (D919G, rs1805087) [14], and reduced folate carrier 1 (RFC1) c.80G>A (R27H, rs1051266) [8,9,15]; Figure 1.

Plasma homocysteine levels were determined by fully automated particle-enhanced immunonephelometry with a BN II System (Dade Behring).

Measurement of DNA methylation

Total DNA was extracted from frozen EDTA-blood using QIAmp DNA Blood Mini Kit (Qiagen, Hilden, Germany). Global methylation status was measured as previously described [16]. Briefly, 0.5-1 μ g of genomic DNA is digested overnight with a 10-fold excess of HpaII or MspI end nuclease according to manufacturer's protocol (New England Biolabs, Beverly,

MA). MspI cuts independently from methylation status at 5'-CCGG-3', while cutting of HpaII depends on the DNA-methylation status. The single nucleotide extension reaction is performed in a 25 µl reaction mixture containing 2 Units of polymerase (Genecraft: Supratherm, Lüdinghausen, Germany), polymerase-buffer (Genecraft) and 0.4 mM Cy5-labelled dCTP (GE Healthcare Europe, Munich, Germany), and incubated at 56° for 1 h on an I-Cycler (Biorad, Hercules, CA) to allow filling of overlapping ends with dCTPs, then placed on ice. Free dCTPs are separated by QIAquick Nucleotide removal kit (Qiagen) and fluorescently labelled DNA is eluted by 100µl of H₂O. Fluorescence is measured on a Molecular Imager FX (Biorad) and quotients of 1-(HpaII/MspI) are calculated from 3 independent experiments [16].

Statistical analysis

The Kolmogorov-Smirnov Test revealed normal distribution of all data analysed. Deviation from Hardy-Weinberg-Equilibrium was tested for all genotypes studied using the online tool of the Institute for Human Genetics, Munich, accessible at <http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>. Mixed linear models (using the restricted estimated maximum likelihood method) were performed to evaluate the impact of the analysed genotypes on global DNA methylation. Akaike's information criterion (AIC) was used to assess the best fitting model. To cope with the family structure within our sample, we computed families as repeated measurements applying a scaled identity covariance structure. Linear regression analysis was used to test associations between the covariates homocysteine, age, smoking, and all tested genotypes and global DNA methylation as dependent variable. Comparison of the global DNA methylation in different genotypes of the same genetic variant was made using one-way analysis of variance (ANOVA).

P-values of less than 0.05 (two-tailed) were considered to indicate statistical significance.

Data were analyzed employing the statistical package for the social sciences (SPSSTM for

Windows 14.0; SPSS Inc., Chicago, IL).

Results

Linear regression analysis revealed no significant influence of age ($B=-0.42$; $P=0.469$) and homocysteine ($B=0.194$; $P=0.392$) on global DNA methylation. Neither did gender (t-Test: $T=0.007$; $df=311$; $P=0.995$) nor smoking status ($T=0.302$; $df=296$; $P=0.763$).

All genotypes studied did not show deviation from Hardy-Weinberg-Equilibrium with the exception of DHFR19. Interestingly, this deviation was only driven by the offspring group in the study population. As we did not observe significant differences in genotype distribution between the three groups (cases, offspring, spouses), we decided to include DHFR into the subsequent analyses. Table 2 provides the investigated genotypes and their association with global DNA methylation. F and P-values were derived from the parameter estimates and corrected for multiple testing using Bonferroni's procedure. We analyzed whether the proportion of variance of DNA methylation derived by the single genotypes was significant. As shown in Table 2, the MTR c.2756A>G genotype was associated with global DNA methylation showing an allele-dosage effect with a higher methylation associated with the wild-type A-allele. This association was only significant for the total sample size, but not, if patients, spouses and offspring were analysed separately. We did not observe any further significant results for all other investigated genotypes (Table 2). We tested our model in a general linear analysis and observed that the MTR c.2756A>G genotype ($p=0.048$; 50.88% of variance), but not age, sex, family status or any interaction between factors and covariates was associated with global DNA methylation. Homocysteine plasma levels were not associated with MTR alleles (ANOVA: $F=0.87$; $p=0.419$). Homocysteine plasma levels did not correlate with methylation (Pearson's correlation: -0.033 ; $p=0.555$).

Discussion

This study shows that the G-allele of MTR c.2756A>G (D919G) is associated with reduced global DNA-methylation.

The genotype frequencies of the current study are within the range reported in other study populations for CBS c.844_855ins68 [10,17], DHFR c.594+59del19bp [11,18], MTHFR c.677C>T [12,19] and c.1298A>C [13,20], RFC1 c.80G>A [15], and MTR c.2756A>G [14,21]. This shows that all genotype frequencies reported in the current study are representative and are not due to the current study population or patient selection.

The mechanism how MTR c.2756A>G leads to reduced global DNA-methylation remains speculative as the biological effect of MTR c.2756A>G is unclear. *In vitro* analyses of the variant enzyme activity are lacking, and associations of the different alleles with homocysteine plasma levels are controversial [22,23]. Paz et al. found that in tumors occurring in individuals who carried 2756GG showed a lower frequency of CpG island hypermethylation in tumor suppressor genes [24]. In the population of our study we did not detect an association between the MTR genotype and homocysteine plasma levels or between homocysteine levels and DNA methylation. This suggests that the MTR variant might have an effect on DNA methylation independent from effects on homocysteine levels, alternatively homocysteine levels might additionally be controlled by altered flux through the transsulfuration or the alternative remethylation pathway based on the enzyme betaine-homocysteine methyltransferase [25].

The G-allele of MTR c.2756A>G has already been reported to decrease the susceptibility to various cancers [26-31]. The observed effect of the G-allele of the MTR c.2756A>G variant on DNA methylation suggests that the protective effect of this variant on several types of cancer may be mediated decreased CpG island methylation, because hypermethylation of DNA repair and tumor suppressor genes can result in the inactivation of these genes resulting

in increased levels of genetic damage, predisposing cells to later genetic instability which then contributes to tumor progression [32]. For example, the tumour suppressor genes Von Hippel–Lindau (*VHL*) in renal cancer and *CDKN2A* in several tumour types are DNA hypermethylated [33,34]. This may also explain why the G-allele of MTR c.2756A>G has been described to be associated with longevity [35].

A recent paper of Weiner et al, described that the homozygous genotype of MTR c.2756GG is associated with increased global DNA methylation when compared to homozygous carriers of the MTRc.2756AA wildtype in their study population of healthy Caucasian Russian blood donors. In addition to that they showed a significant decrease of global DNA methylation in homozygous MTHFR c.677TT carries in comparison to probands with the MTHFR c.677CC genotype [36]. The difference between this study and the current data might be explained by differences in populations and other factors influencing DNA methylation such as folate levels, alcohol consumption, and smoking [37,38].

Finally, it is tempting to speculate about possible clinical implications of the data presented. MTR activity depends on folate and vitamin B12 [25], which might provide a link of nutritional factors, epigenetics and cancer development [39]. Additional studies on the functional consequences of the MTR c.2756A>G polymorphism and of folate and vitamin B12 on the DNA methylation patterns are warranted.

Our results are limited due to different factors: First, we did not analyze a population based cohort, but families with at least one person suffering from vascular disease. However, in all subgroups defined by family status, results tended in the same direction making it unlikely that the overall effect is driven by a specific effect in vascular patients only. Second, we did not investigate genetically independent subjects, but family members. We tried to control for this influence in the mixed models by treating family members as linked samples and modeling the covariance structure accordingly. Further, the power of the study might not have been sufficient to detect small effects of genotypes on DNA methylation. In a study of 384

healthy Japanese women, the amount of dietary folate intake, but not MTR c.2756A>G, was associated with global methylation of leukocyte levels [40]. Methionine metabolism is strongly influenced by folate and vitamin B12 intake and blood levels, and such parameters were not measured in our study. Thus, we cannot decide whether differences in these parameters might have contributed to the discrepancy of the results between the Japanese and our study population.

Future perspective

Global DNA methylation is an important epigenetic mechanism and associated with clinically important diseases such as cancer. This study shows that the G-allele of MTR c.2756A>G (D919G) is associated with reduced global DNA-methylation. Future studies have to describe the further mechanisms leading to altered DNA methylation including other genetic variations, but also environmental influences like nutrition or medications. Probably there is a complex interplay between all factors leading to altered DNA methylation and precise characterization of the study population is essential to achieve meaningful results.

Executive Summary

- The origin of altered DNA methylation is unknown.
- In a cohort of 313 individuals we observed an association of the G-allele of the methionine synthase variant c.2756A>G (D919G) with global methylation.
- Our data suggest that an impact on DNA methylation may contribute to the clinical relevance of the methionine synthase variant.

Table 1. Polymorphisms and global leukocyte CpG island methylation

Variant rs number/Genbank No.	genotype number of individuals (%) global DNA methylation			ANOVA	HWE (Pearson's)
CBS c.844_855ins68 S78267.1	del/del: 274 (87.5%) 39.3±16.2	del/ins: 38 (12.1%) 37.2±18.8	ins/ins: 1 (0.3%) 34.4	F=1.237 p=0.292	F=-0.015 p=0.83
DHFR c.594+59del19bp NM_000791.3	del/del: 70 (22.4%) 40.0±16.0	del/ins: 134 (42.8%) 38.9±16.7	ins/ins: 109 (34.8%) 38.0±16.9	F=0.313 p=0.732	F=0.13 p=0.02 [#]
MTHFR c.677C>T rs1801133	CC: 151 (48.2%) 38.6±15.9	CT: 139 (44.4%) 39.6±17.4	TT: 23 (7.3%) 36.3±16.0	F=0.396 p=0.673	F=-0.062 p=0.27
MTHFR c.1298A>C rs1801131	AA: 151 (48.2%) 39.4±16.1	AC: 136 (43.4%) 38.8±17.5	CC: 26 (8.3%) 36.1±14.4	F=0.742 p=0.477	F=-0.029 p=0.60
RFC1 c.80G>A rs1051266	GG: 102 (32.6%) 40.6±19.1	AG: 149 (47.6%) 39.7±16.1	AA: 62 (19.8%) 36.6±15.4	F=1.534 p=0.217	F=0.037 p=0.51
MTR c.2756A>G rs1805087	AA: 184 (58.8%) 41.3±14.9	AG: 112 (35.8%) 36.4±18.2	GG: 17 (5.4%) 30.8±16.9	F=4.799 p=0.009*	F=-0.012 p=0.83
MTR c.2756A>G Patients only	AA: 50 (58.8%) 33.5±21.3	AG: 30 (35.3%) 32.9±24.0	GG: 5 (5.9%) 16.1±38.9	F=1.279 p=0.284	F=-0.012 p=0.91
MTR c.2756A>G Spouses only	AA: 42 (61.8%) 38.3±19.9	AG: 22 (32.4%) 34.6±21.8	GG: 4 (5.9%) 27.0±21.5	F=1.599 p=0.205	F=0.059 p=0.63
MTR c.2756A>G Offspring only	AA: 92 (57.5%) 38.3±19.9	AG: 60 (37.5%) 34.6±21.8	GG: 8 (5.0%) 27.0±21.5	F=1.599 p=0.205	F=-0.047 p=0.60

Table 1: All tested genetic variants of the methionine metabolism and their association with global DNA methylation. The MTR variant c.2756A>G (allele-dosage effect with the wildtype A-allele) was significantly associated with global DNA methylation (*). CBS (cystathionine beta-synthase), DHFR (dihydrofolate reductase), MTHFR (5,10-

methylenetetrahydrofolate reductase), MTR (5-methyltetrahydrofolate-homocysteine S-methyltransferase), RFC (reduced folate carrier).

Figure 1. Methionine-homocysteine metabolism




Figure 1: In human methionine metabolism methionine becomes activated to S-adenosylmethionine (SAM) via methionine adenosyltransferase (MAT). SAM is an ubiquitous methyl group donor, e.g., for the synthesis of biogenic amines and DNA methylation. Degradation product of SAM is S-adenosylhomocysteine (SAH), which is hydrolyzed to homocysteine per homocysteine hydrolase (SAHH). Hcys can either be transsulfurated to cystathionine and cysteine via vitamin B6-dependent cystathionine beta-synthase (CBS) and cystathionine gamma lyase (CGL), or alternatively, homocysteine can be remethylated to methionine. This is done by 5-methyltetrahydrofolate-homocysteine S-

methyltransferase (MTR, also called methionine synthase), which needs a derivate of vitamin B12 (methylcobalamin) as well as a derivate of folate (5-methyltetrahydrofolate; 5-MTHF) as cofactors. Vitamin B12 is transported by transcobalamin 2 (Tc2), and 5-methyltetrahydrofolate is synthesized by 5,10-methylenetetrahydrofolate reductase (MTHFR) from 5,10-methylenetetrahydrofolate (5,10-MTHF), which is synthesized from folate by dihydrofolate reductase (DHFR) in two subsequent steps.

Figure 2. Impact of MTR c.2756A>G on global DNA methylation




Figure 2: MTR c.2756 A>G genotypes and global DNA methylation. P values given are derived from the all pairwise comparison of the estimated marginal means and are corrected according to Bonferroni.

References

1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. *Nat Rev Genet*, 3(6), 415-428 (2002).
2. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. *Nat Rev Genet*, 14(11), 765-780 (2013).
3. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? *Cancer Cell*, 22(1), 9-20 (2012).
4. Yan XJ, Xu J, Gu ZH *et al.* Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. *Nat Genet*, 43(4), 309-315 (2011).
5. Kanai Y, Ushijima S, Nakanishi Y, Sakamoto M, Hirohashi S. Mutation of the DNA methyltransferase (DNMT) 1 gene in human colorectal cancers. *Cancer Lett*, 192(1), 75-82 (2003).
6. Turcan S, Rohle D, Goenka A *et al.* IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. *Nature*, 483(7390), 479-483 (2012).
7. Stover PJ. Polymorphisms in 1-carbon metabolism, epigenetics and folate-related pathologies. *J Nutrigenet Nutrigenomics*, 4(5), 293-305 (2011).
8. Linnebank M, Moskau S, Farmand S *et al.* Homocysteine and Carotid Intima-Media Thickness in a German Population. Lack of Clinical Relevance. *Stroke*, (2006).

9. Moskau S, Golla A, Grothe C, Boes M, Pohl C, Klockgether T. Heritability of carotid artery atherosclerotic lesions: an ultrasound study in 154 families. *Stroke*, 36(1), 5-8 (2005).
10. Tsai MY, Bignell M, Schwichtenberg K, Hanson NQ. High prevalence of a mutation in the cystathionine beta-synthase gene. *Am J Hum Genet*, 59(6), 1262-1267 (1996).
11. Johnson WG, Stenroos ES, Spychala JR, Chatkupt S, Ming SX, Buyske S. New 19 bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR): a risk factor for spina bifida acting in mothers during pregnancy? *Am.J.Med.Genet.A*, 124(4), 339-345 (2004).
12. Frosst P, Blom HJ, Milos R *et al.* A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat.Genet.*, 10(1), 111-113 (1995).
13. van der Put NM, Gabreels F, Stevens EM *et al.* A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? *Am.J.Hum.Genet.*, 62(5), 1044-1051 (1998).
14. Leclerc D, Campeau E, Goyette P *et al.* Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. *Hum Mol Genet*, 5(12), 1867-1874 (1996).
15. Chango A, Emery-Fillon N, de Courcy GP *et al.* A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. *Mol Genet Metab*, 70(4), 310-315 (2000).

16. Bleich S, Lenz B, Ziegenbein M *et al.* Epigenetic DNA hypermethylation of the HERP gene promoter induces down-regulation of its mRNA expression in patients with alcohol dependence. *Alcohol Clin Exp Res*, 30(4), 587-591 (2006).
17. Ouyang S, Liu Z, Li Y, Ma F, Wu J. Cystathionine beta-synthase 844ins68 polymorphism is unrelated to susceptibility to neural tube defects. *Gene*, 535(2), 119-123 (2014).
18. Parle-McDermott A, Pangilinan F, Mills JL *et al.* The 19-bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR) may decrease rather than increase risk for spina bifida in the Irish population. *Am J Med Genet A*, 143A(11), 1174-1180 (2007).
19. van Driel LM, Verkleij-Hagoort AC, de Jonge R *et al.* Two MTHFR polymorphisms, maternal B-vitamin intake, and CHDs. *Birth Defects Res A Clin Mol Teratol*, 82(6), 474-481 (2008).
20. Richter B, Stegmann K, Roper B, Boddeker I, Ngo ET, Koch MC. Interaction of folate and homocysteine pathway genotypes evaluated in susceptibility to neural tube defects (NTD) in a German population. *J Hum Genet*, 46(3), 105-109 (2001).
21. Xia J, Wang Y, Zhang H, Hu Y. Association between MTR A2756G polymorphism and childhood acute lymphoblastic leukemia: a meta-analysis. *Leuk Lymphoma*, (2013).
22. Matsuo K, Suzuki R, Hamajima N *et al.* Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. *Blood*, 97(10), 3205-3209 (2001).

23. Goode EL, Potter JD, Bigler J, Ulrich CM. Methionine synthase D919G polymorphism, folate metabolism, and colorectal adenoma risk. *Cancer Epidemiol Biomarkers Prev*, 13(1), 157-162 (2004).
24. Paz MF, Avila S, Fraga MF *et al.* Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. *Cancer Res.*, 62(15), 4519-4524 (2002).
25. Mudd SH, Levy HL, Kraus JP. Disorders of transsulfuration. (Ed.^(Eds) (Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler K, Vogelstein B. Editors, New York: Mc Graw-Hill, 2001) 2007-2056.
26. Linnebank M, Schmidt S, Kolsch H *et al.* The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma. *Br.J.Cancer*, 90(10), 1969-1971 (2004).
27. Ma J, Stampfer MJ, Christensen B *et al.* A polymorphism of the methionine synthase gene: association with plasma folate, vitamin B12, homocyst(e)ine, and colorectal cancer risk. *Cancer Epidemiol.Biomarkers Prev.*, 8(9), 825-829 (1999).
28. Ulvik A, Vollset SE, Hansen S, Gislefoss R, Jellum E, Ueland PM. Colorectal cancer and the methylenetetrahydrofolate reductase 677C -> T and methionine synthase 2756A -> G polymorphisms: a study of 2,168 case-control pairs from the JANUS cohort. *Cancer Epidemiol.Biomarkers Prev.*, 13(12), 2175-2180 (2004).
29. Henao OL, Piyathilake CJ, Waterbor JW *et al.* Women with polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MS) are less likely to have cervical intraepithelial neoplasia (CIN) 2 or 3. *Int.J.Cancer*, 113(6), 991-997 (2005).

30. Gemmati D, Ongaro A, Scapoli GL *et al.* Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. *Cancer Epidemiol.Biomarkers Prev.*, 13(5), 787-794 (2004).
31. Lincz LF, Scorgie FE, Kerridge I, Potts R, Spencer A, Enno A. Methionine synthase genetic polymorphism MS A2756G alters susceptibility to follicular but not diffuse large B-cell non-Hodgkin's lymphoma or multiple myeloma. *Br.J.Haematol.*, 120(6), 1051-1054 (2003).
32. Strathdee G, Brown R. Aberrant DNA methylation in cancer: potential clinical interventions. *Expert Rev Mol Med*, 4(4), 1-17 (2002).
33. Jones PA, Baylin SB. The epigenomics of cancer. *Cell*, 128(4), 683-692 (2007).
34. Esteller M. Epigenetics in cancer. *N Engl J Med*, 358(11), 1148-1159 (2008).
35. Linnebank M, Fliessbach K, Kolsch H, Rietschel M, Wullner U. The methionine synthase polymorphism c.2756Aright curved arrow G (D919G) is relevant for disease-free longevity. *Int.J.Mol.Med.*, 16(4), 759-761 (2005).
36. Weiner AS, Boyarskikh UA, Voronina EN, Mishukova OV, Filipenko ML. Methylenetetrahydrofolate reductase C677T and methionine synthase A2756G polymorphisms influence on leukocyte genomic DNA methylation level. *Gene*, 533(1), 168-172 (2014).
37. Varela-Rey M, Woodhoo A, Martinez-Chantar ML, Mato JM, Lu SC. Alcohol, DNA methylation, and cancer. *Alcohol research : current reviews*, 35(1), 25-35 (2013).

38. Thapar M, Covault J, Hesselbrock V, Bonkovsky HL. DNA methylation patterns in alcoholics and family controls. *World J Gastrointest Oncol*, 4(6), 138-144 (2012).
39. Su LJ. Diet, epigenetics, and cancer. *Methods Mol Biol*, 863, 377-393 (2012).
40. Ono H, Iwasaki M, Kuchiba A *et al.* Association of dietary and genetic factors related to one-carbon metabolism with global methylation level of leukocyte DNA. *Cancer Sci*, 103(12), 2159-2164 (2012).

Highlighted References

Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. *Nat Rev Genet*, 14(11), 765-780 (2013).

** very concise review about the interplay between genetic and epigenetic variations in cancer

Ono H, Iwasaki M, Kuchiba A *et al.* Association of dietary and genetic factors related to one-carbon metabolism with global methylation level of leukocyte DNA. *Cancer Sci*, 103(12), 2159-2164 (2012).

*describes the influence of diet on methionine metabolism and DNA methylation

Matsuo K, Suzuki R, Hamajima N *et al.* Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. *Blood*, 97(10), 3205-3209 (2001).

*early report describing the clinical relevance of genetic variants of the methionine metabolism